
|Articles|April 1, 2003
Efalizumab Efficiency
San Francisco -- Results from Phase III clinical trials support the efficacy and safety of efalizumab (Raptiva), the humanized CD-11a monoclonal antibody, as a chronic treatment for moderate-to-severe plaque psoriasis, Kim A. Papp, M.D., said at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 2
4
Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases
5

















